Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page & i8 c% u; m2 E4 s+ v9 a4 Q
- L4 q! ^& j2 u6 g6 l5 p/ Q# U( D/ }
Sub-category:
8 Y# u. a9 o1 b/ z9 _" s* t1 g4 aMolecular Targets : Y9 T8 H9 |3 }" s3 w. z4 e6 h
, j6 m% F& }7 b& c* t- o' Y
; G! t5 U" {: y* O- `, f
Category:
4 d Y" s" Y; @; PTumor Biology 5 l. Q8 ?" m1 z3 ~
- \1 L. g. [$ {) n2 B' k" p) C) f* Y' Z8 K3 m
Meeting:' Q9 Y o5 _% i3 }9 c
2011 ASCO Annual Meeting 1 S6 ?5 B; g2 F
% R2 k) f7 w' x+ S, w& S3 {% H+ s R
Session Type and Session Title:
$ B1 r: G7 K6 yPoster Discussion Session, Tumor Biology
' Q/ p+ }7 a( a+ q" T& c3 n( _
6 y- L- [9 Y2 H6 i y+ A, `, ^ k9 B; W6 y; R$ f @
Abstract No:, X, N& Q! J. S9 f
10517
& X) I3 }0 Z% ~; c( c
) d3 @' C' \% |0 M, z/ @4 I% q1 C4 Y; a5 o; a
Citation:
2 e1 P4 Z0 x' DJ Clin Oncol 29: 2011 (suppl; abstr 10517) $ B, Q% H5 d/ |1 O4 ~
8 G! X) @. ~/ s6 t
7 N. ?: S! C4 p- W5 nAuthor(s):) i' B% y% G6 R" {3 B$ q' h
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* k9 N, `( M E, V2 M+ W/ P
8 [" H4 q; J! s4 v s8 E
0 X' A0 x1 T/ K3 x
5 H |7 ?1 h l- U+ } t8 Q$ WAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
" V) O8 \6 l9 |. L% H H/ Q# {3 c
5 i: u9 A" d' bAbstract Disclosures
6 D( v2 [. C& p7 I5 g2 C3 r: N' k) G+ R; ^
Abstract:
- g# O7 @0 P0 v9 P+ P# [1 V9 C+ } p7 ~. K! J9 @
" l' c% k9 ^9 T$ {Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- j4 z y/ N/ G) I/ c4 E0 o
) x% n, T9 b* r
% U1 I0 J1 b; c( W/ f p |
显身卡
